ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Four Indoco Remedies promoters bought 20,740 shares on NSE on 5 November 2026. Aggregate purchase value is about Rs.0.45 Crore.
Indoco Remedies promoter and director Suresh G Kare bought 1,335 equity shares on the open market on 6 November 2026, raising holding from 1.42% to 1.42%. The trade value is Rs.2,84,248, about Rs.0.03 Crore.
Indoco Remedies promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a combined 5,996 equity shares via market purchase. The total transaction value is ₹0.13 Crore.
Indoco Remedies' promoters Aditi Panandikar and Madhura Suresh Kare acquired 8,004 shares via market purchase. The total transaction value is ₹0.17 Crore.
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Indoco Remedies Ltd reported revenue from operations of ₹506.9 Cr (+7.4% YoY) and net profit of ₹19.5 Cr for Q2 FY27.
Indoco Remedies allotted 14,850 ESOP shares to its Employees Welfare Trust under the 2022 ESOP plan. The allotment is at face value with no transaction price.
Indoco Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in accordance with SEBI Regulation 31(1)(b).
Indoco Remedies intimated a board meeting on 27 Oct 2026 to approve Q1 FY27 standalone and consolidated results. Trading window remains closed until 29 Oct 2026.
Indoco Remedies Limited is incorporating a new wholly owned subsidiary, Warren Lifesciences Private Limited, for a cash investment of ₹0.01 Crore.
Indoco Remedies Limited has incorporated a new wholly-owned subsidiary, Warren Lifesciences Private Limited, to manufacture and develop pharmaceutical products.
Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.
Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.
Indoco Remedies filed proceedings of its 79th AGM held on 17 September 2026. Shareholders voted on nine resolutions including dividend and borrowing limits.